THE PARTNER 3 TRIAL

PARTNER 3

Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Martin B. Leon, MD &
Michael J. Mack, MD
on behalf of the PARTNER 3 Trial Investigators

Disclosures - Martin B. Leon, MD

ACC 2019; New Orleans, LA; March 16-18, 2019

Within the past 36 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Financial Relationship	Company
• Research Support	Abbott, Boston Scientific, Edwards Lifesciences, Medtronic
• Consulting Fees*	Abbott, Boston Scientific, Gore, Medtronic, Meril Life Sciences
• Other	Edwards Lifesciences**

*Medical or scientific advisory board meetings

** Co-PI PARTNER 3 Trial; travel-related expenses only

THE PARTNER 3 TRIAL

Background (1)

- Previous PARTNER studies have shown that TAVR was superior to standard therapy in extreme-risk patients and non-inferior to surgery in high- and intermediate-risk patients.
- Over the past decade, technology enhancements and procedural refinements have reduced complications and improved clinical outcomes after TAVR.
- The majority of AS patients treated with surgery have low surgical risk profiles and TAVR vs. surgery in such patients has not been investigated in rigorous clinical trials.

Background (2)

PARTNER 3

- RCT 1:1
- vs. Surgery
- N = 1000 pts

Low Risk



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 OCTOBER 21, 2010 VOL. 363 NO. 17

Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery

Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D., Raj R. Makkar, M.D., David L. Brown, M.D., Peter C. Block, M.D., Robert A. Guyton, M.D., Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D., Howard C. Herrmann, M.D., Pamela S. Douglas, M.D., John L. Petersen, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D., and Stuart Pocock, Ph.D., for the PARTNER Trial Investigators*



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 APRIL 28, 2016 VOL. 374 NO. 17

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients

Martin B. Leon, M.D., Craig R. Smith, M.D., Michael J. Mack, M.D., Raj R. Makkar, M.D., Lars G. Svensson, M.D., Ph.D., Susheel K. Kodali, M.D., Vinod H. Thourani, M.D., E. Murat Tuzcu, M.D., D. Craig Miller, M.D., Howard C. Herrmann, M.D., Darshan Doshi, M.D., David J. Cohen, M.D., Augusto D. Pichard, M.D., Samir Kapadia, M.D., Todd Dewey, M.D., Vasilis Babaliaros, M.D., Wilson Y. Szeto, M.D., Mathew R. Williams, M.D., Dean Kereiakes, M.D., Alan Zajarias, M.D., Kevin L. Greason, M.D., Brian K. Whisenant, M.D., Robert W. Hodson, M.D., Jeffrey W. Moses, M.D., Alfredo Trento, M.D., David L. Brown, M.D., William F. Fearon, M.D., Philippe Pibarot, D.V.M., Ph.D., Rebecca T. Hahn, M.D., Wael A. Jaber, M.D., William N. Anderson, Ph.D., Maria C. Alu, M.M., and John G. Webb, M.D., for the PARTNER 2 Investigators*

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 JUNE 9, 2011 VOL. 364 NO. 23

Transcatheter and Surgical Aortic-Valve Replacement in High-Risk Patients

Craig R. Smith, M.D., Martin B. Leon, M.D., Michael J. Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D., Raj R. Makkar, M.D., Mathew Williams, M.D., Todd Dewey, M.D., Samir Kapadia, M.D., Vasilis Babaliaros, M.D., Vinod H. Thourani, M.D., Paul Corso, M.D., Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D., Howard C. Herrmann, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D., and Stuart J. Pocock, Ph.D., for the PARTNER Trial Investigators*

THE PARTNER 3 TRIAL

Purpose

To compare the safety and effectiveness of the SAPIEN 3 TAVR system versus conventional surgery in patients with severe symptomatic aortic stenosis who are at *low surgical risk*.

THE PARTNER 3 TRIAL

PARTNER 3 Study Design



PRIMARY ENDPOINT:
Composite of all-cause mortality, stroke, or CV re-hospitalization at 1 year post-procedure

PARTNER 3 Clinical Sites

THE PARTNER 3 TRIAL

THE PARTNER 3 TRIAL

Top Enrolling Sites

Heart Hospital Baylor Plano, Plano, TX	David Brown and Michael Mack	68 pts
Emory University, Atlanta, GA	Vasilis Babaliaros and Robert Guyton	52 pts
Columbia University Med Ctr, New York, NY	Isaac George, Susheel Kodali, and Tamim Nazif	41 pts
Cedars-Sinai Med Ctr, Los Angeles, CA	Raj Makkar and Alfredo Trento	35 pts
Newark Beth Israel Med Ctr, Newark, NJ	Bruce Haik and Mark Russo	34 pts
NYU Langone Med Ctr, New York, NY	Mathew Williams	33 pts
Northwestern University, Chicago, IL	Charles Davidson and Chris Malaisrie	27 pts
University of Washington, Seattle, WA	Gabriel Aldea and James McCabe	24 pts
Atlantic Health System, Morristown, NJ	John Brown and Robert Kipperman	23 pts
Banner University Phoenix, Phoenix, AZ	Kenith Fang and Ashish Pershad	23 pts
Lankenau Med Ctr, Wynnewood, PA	Paul Goady and Scott Goldman	23 pts
Henry Ford Hospital, Detroit, MI	William O'Neill and Gaetano Paone	21 pts
Saint Thomas Health, Nashville, TN	Andrew Moore and Evelio Rodriguez	21 pts
UC Health Rockies, Loveland, CO	Mark Guadagnoli and Brad Oldemeyer	21 pts
Mills-Peninsula Med Ctr, Burlingame, CA	David Daniels and Conrad Vial	20 pts

The PARTNER 3 Trial

Top 5 Enrolling Sites


David Brown and Michael Mack
Heart Hospital Baylor Plano; Plano, TX
68 patients enrolled




Robert Guyton and Vasilis Babaliaros
Emory University; Atlanta, GA
52 patients enrolled



Susheel Kodali, Isaac George and Tamim Nazif
Columbia University Med Center; NY, NY
41 patients enrolled


Raj Makkar and Alfredo Trento
Cedars-Sinai Med Center; Los Angeles, CA
35 patients enrolled


Mark Russo and Bruce Haik
Newark Beth Israel Med Center; Newark, NJ
34 patients enrolled

THE PARTNER 3 TRIAL

Study Leadership

National Principal Investigators

- Martin B. Leon, MD, Columbia University Medical Center, New York, NY
- Michael J. Mack, MD, The Heart Hospital Baylor Plano, Plano, TX

Steering Committee

- Howard Herrmann, Samir Kapadia, Susheel Kodali, Martin B. Leon, Michael J. Mack, Raj Makkar, Craig R. Smith (chair), Wilson Szeto, Vinod Thourani, John Webb

Data & Safety Monitoring Board

- Cardiovascular Research Foundation, New York, NY; Joseph Carrozza, Jr., MD, chair

Clinical Events Committee

- Cardiovascular Research Foundation, New York, NY; Steven O. Marx, MD, chair

CT Core Laboratory

- The University of British Columbia; Jonathon Leipsic, MD, chair; Philipp Blanke, MD, chair

Echocardiographic Core Laboratory

- Quebec Heart & Lung Institute (Laval University); Philippe Pibarot, DVM PhD, chair
- Cardiovascular Research Foundation, New York, NY; Rebecca Hahn, MD, chair

Sponsor

- Edwards Lifesciences, Irvine, CA

THE PARTNER 3 TRIAL

Key Inclusion Criteria

Severe Calcific Aortic Stenosis

- AVA ≤ 1.0 cm^2 or AVA index ≤ 0.6 cm^2/m^2
- Jet velocity ≥ 4.0 m/s or mean gradient ≥ 40 mmHg, AND
  - NYHA Functional Class ≥ 2, OR
  - Abnormal exercise test with severe SOB, abnormal BP response, or arrhythmia, OR
  - Asymptomatic with LVEF < 50%

Low Surgical Risk

- Determined by multi-disciplinary heart team
- STS < 4%
- Adjudicated by case review board

THE PARTNER 3 TRIAL

Key Exclusion Criteria

Anatomic

- Aortic annulus diameter < 16 mm or > 28 mm (3D imaging)
- Bicuspid valve (CT imaging)
- Severe AR (> 3+) or MR (> 3+)
- Severe LV dysfunction (LVEF < 30%)
- Severe calcification of aortic valvar complex (esp. LVOT)
- Vascular anatomy not suitable for safe femoral access
- Complex CAD: ULM, Syntax score > 32, or not amenable for PCI
- Low coronary takeoff (high risk for obstruction)

Clinical

- Acute MI within 1 month
- Stroke or TIA within 90 days
- Renal insufficiency (eGFR < 30 ml/min) and/or renal replacement Rx
- Hemodynamic or respiratory instability
- Frailty (objective assessment; > 2/4+ metrics)

THE PARTNER 3 TRIAL

SAPIEN Valve Evolution

	SAPIEN	SAPIEN XT	SAPIEN 3
Valve Technology			
Sheath Compatibility			
Available Valve Sizes			
FDA Approval of Valve:	**PARTNER 1** 2011	**PARTNER 2** 2014	**PARTNER 3** 2015

THE PARTNER 3 TRIAL

Study Methodology

- Every patient reviewed (including imaging studies) by multi-disciplinary heart team AND case review board
- Baseline and 30-day neuro assessment in all patients; serial neurologist examinations and neuro-imaging for suspected neuro events
- 3D cardiac imaging (CT or TEE) prior to randomization
- Same day or staged concomitant PCI procedures (or surgery + CABG) were allowed if approved during case review
- 100% CEC adjudication of all major endpoint events (VARC-2 definitions when applicable)
- 10-year clinical and echocardiography follow-up in all patients

THE PARTNER 3 TRIAL

Primary Endpoint

- **Non-hierarchical composite of all-cause mortality, all strokes, or CV re-hospitalization at 1 year**
  - Primary analysis was non-inferiority, followed by superiority
  - Analysis cohort was the ‘as-treated’ (AT) population, defined as all randomized patients in whom the procedure was initiated.
  - Multiple sensitivity analyses performed

THE PARTNER 3 TRIAL

Sample Size Calculation

- **Primary hypothesis:** non-inferiority SAPIEN 3 vs. surgery for the primary endpoint at 1 year
- **Non-inferiority margin:** 6% (risk difference)
- **One-sided alpha:** 0.025
- **Assumptions** (for 1:1 randomization)
  - Event rate: 16.6% for Surgery and 14.6% for TAVR
- **Power:** 90%
- **Sample size:** 864 patients (increased to 1,000 patients for loss to follow-up, withdrawals and other contingencies)

THE PARTNER 3 TRIAL

Statistical Methods

- **Non-inferiority Testing for Primary Endpoint**
  - Upper bound of the 95% CI for the risk difference (TAVR-surgery) less than the pre-specified non-inferiority margin of 6%
- **Superiority Testing for Primary Endpoint**
  - If non-inferiority hypothesis met, superiority testing performed using a 2-sided alpha 0.05
- **Superiority Testing for Secondary Endpoints**
  - 1) Pre-specified in hierarchical order with multiplicity adjustments and 2) all others (P-values hypothesis generating)

Study Flow and Follow-Up

1520 patients with severe symptomatic AS at low surgical risk consented between March 25, 2016 and October 26, 2017 at 71 sites in the US, Canada, Japan, ANZ

Excluded from Randomization N=520

- Anatomic exclusions (n=308)
- Clinical exclusions (n=89)
- Other exclusions (n=38)
- Incomplete screening (n=85)

Eligible for Enrollment and Randomized N=1000 at 71 sites

TAVR N=503

Surgery N=497

THE PARTNER 3 TRIAL

Study Populations

ITT to AT Patient Cohorts



Patient Disposition



*4 patients who withdrew from the surgery arm are considered to have complete 1-yr follow-up b/c they had already experienced an endpoint event prior to withdrawing from the study.

Baseline Patient Characteristics

THE PARTNER 3 TRIAL

% or mean ± SD

Demographics & Vascular Disease	TAVR (N=496)	Surgery (N=454)	Other Co-Morbidities	TAVR (N=496)	Surgery (N=454)
Age (years)	73.3 ± 5.8	73.6 ± 6.1	Diabetes	31.3%	30.2%
Male	67.5%	71.1%	COPD (any)	5.1%	6.2%
BMI – kg/m^2	30.7 ± 5.5	30.3 ± 5.1	Pulmonary Hypertension	4.6%	5.3%
STS Score	1.9 ± 0.7	1.9 ± 0.6	Creatinine > 2mg/dL	0.2%	0.2%
NYHA Class III or IV*	31.3%	23.8%	Frailty (overall; > 2/4+)	0	0
Coronary Disease	27.7%	28.0%	Atrial Fibrillation (h/o)	15.7%	18.8%
Prior CABG	3.0%	1.8%	Permanent Pacemaker	2.4%	2.9%
Prior CVA	3.4%	5.1%	Left Bundle Branch Block	3.0%	3.3%
Peripheral Vascular Disease	6.9%	7.3%	Right Bundle Branch Block	10.3%	13.7%

*p = 0.01

Baseline Echo and CT Characteristics

% or mean ± SD

Characteristic	TAVR (N=496)	Surgery (N=454)
Aortic Valve Area (cm^2)	0.8 ± 0.2	0.8 ± 0.2
Mean Gradient (mmHg)	49.4 ± 12.8	48.3 ± 11.8
LVEF (%)	65.7 ± 9.0	66.2 ± 8.6
LV Mass Index (g/m^2)	104.5 ± 25.7	101.5 ± 25.4
≥ Moderate MR	1.3%	3.2%
≥ Moderate AR	3.9%	2.5%
≥ Moderate TR	1.7%	2.3%
CT – Annulus Perimeter (mm)	78.1 ± 6.9	78.6 ± 7.2
CT – Annulus Area (mm^2)	473.5 ± 83.3	479.6 ± 87.6

Procedural & Hospital Findings

% or mean ± SD

Variable	TAVR (N=496)	Surgery (N=454)	P-value
Conscious Sedation	65.1%	NA	NA
Procedure Time (min)	58.6 ± 36.5	208.3 ± 62.2	<0.001
Fluoroscopy Time (min)	13.9 ± 7.1	NA	NA
Aortic Cross-Clamp Time (min)	NA	74.3 ± 27.8	NA
Total CPB Time (min)	NA	97.7 ± 33.8	NA
Median ICU Stay (days)	2.0	3.0	<0.001
Median Total LOS (days)	3.0	7.0	<0.001
Discharge to Home/Self-care	96.0%	73.1%	<0.001
Concomitant Procedures	7.9%	26.4%	<0.001

Procedural Complications

In-Hospital

% or mean ± SD

Complication	TAVR (N=496)	Surgery (N=454)	P-value
In-hospital Death	0.4% (2)	0.9% (4)	0.43
≥ 2 Transcatheter Valves Implanted*	0.2% (1)	NA	NA
Valve Embolization	0	NA	NA
Aortic Dissection	0	NA	NA
Annular Rupture	0.2% (1)	NA	NA
Ventricular Perforation	0.2% (1)	0.4% (2)	0.61
Coronary Obstruction	0.2% (1)	0.4% (2)	0.61
Access Site Infections	0.4% (2)	1.3% (6)	0.16

*Valve-in-valve

THE PARTNER 3 TRIAL

Primary Endpoint



Number at risk:

Surgery	**454**	**408**	**390**	**381**	**377**	**374**
TAVR	**496**	**475**	**467**	**462**	**456**	**451**

THE PARTNER 3 TRIAL

All-Cause Mortality



Number at risk:

Surgery	**454**	**445**	**438**	**433**	**431**	**427**
TAVR	**496**	**494**	**494**	**493**	**492**	**488**

THE PARTNER 3 TRIAL

All Stroke



Number at risk:

Surgery	**454**	**435**	**427**	**423**	**421**	**417**
TAVR	**496**	**491**	**491**	**489**	**487**	**484**

THE PARTNER 3 TRIAL

Death or Disabling Stroke



Number at risk:

Surgery	**454**	**444**	**436**	**432**	**430**	**426**
TAVR	**496**	**494**	**494**	**493**	**491**	**488**

THE PARTNER 3 TRIAL

Rehospitalization



Number at risk:

Surgery	**454**	**416**	**399**	**389**	**385**	**382**
TAVR	**496**	**477**	**469**	**465**	**459**	**453**

THE PARTNER 3 TRIAL

Primary Endpoint Sensitivity Analyses

Intention-to-Treat Population



Number at risk:

Surgery	**497**	**420**	**395**	**382**	**378**	**374**
TAVR	**503**	**478**	**469**	**462**	**456**	**451**

THE PARTNER 3 TRIAL

Primary Endpoint Sensitivity Analyses

Multiple Imputation

	TAVR (N=503)	Surgery (N=497)	KM Rate Difference (TAVR – Surgery)	95% CI* for the Difference	P-value (non-inf)	HR	95% CI for the HR	P-value (sup)
Missing at Random	8.5%	15.2%	-6.7%	(-10.7%, -2.7%)	Pass <0.001	0.53	(0.37, 0.78)	<0.001
Informative Missing	8.6%	15.2%	-6.6%	(-10.6%, -2.6%)	Pass <0.001	0.54	(0.37, 0.78)	<0.001

*95% CI based on the Greenwood standard error

WIN Ratio

Item	Value	P-value
Total no. of pairs	454 X 496 = 225,184	
Win ratio for composite (total wins in TAVR / total wins in Surgery)	1.88	0.001
95% CI*	[1.29, 2.76]	

*95% CI and p-value is based on the Finkelstein and Schoenfeld approach

Primary Endpoint - Subgroup Analysis

Subgroup	TAVR	Surgery	Diff [95% CI]	P-value*
Overall	**8.5**	**15.1**	**-6.6 [-10.8, -2.5]**	
Age				
≤ 74 (n=516)	10.6	14.9	-4.3 [-10.1, 1.5]	**0.21**
> 74 (n=434)	5.8	15.3	-9.5 [-15.3, -3.7]	
Sex				
Female (n=292)	8.1	18.5	-10.4 [-18.3, -2.5]	**0.27**
Male (n=658)	8.7	13.8	-5.1 [-9.9, -0.3]	
STS Score				
≤ 1.8 (n=464)	9.1	15.7	-6.7 [-12.6, -0.7]	**0.98**
> 1.8 (n=486)	8.0	14.5	-6.5 [-12.2, -0.8]	
LV Ejection Fraction				
≤ 65 (n=384)	9.6	17.2	-7.6 [-14.5, -0.7]	**0.48**
> 65 (n=524)	8.0	12.4	-4.4 [-9.6, 0.7]	
NYHA Class				
I/II (n=687)	6.8	14.5	-7.8 [-12.4, -3.2]	**0.54**
III/IV (n=263)	12.3	16.9	-4.7 [-13.5, 4.1]	
Atrial Fibrillation				
No (n=786)	7.9	14.0	-6.1 [-10.5, -1.7]	**0.67**
Yes (n=163)	11.6	20.3	-8.7 [-19.9, 2.5]	
KCCQ Overall Summary Score				
≤ 70 (n=407)	10.5	19.9	-9.4 [-16.5, -2.4]	**0.27**
> 70 (n=536)	6.5	11.2	-4.6 [-9.4, 0.2]	



Event rates are KM estimates (%)

* P-value is for interaction

THE PARTNER 3 TRIAL

Pre-specified Secondary Endpoints

Subject to Multiplicity Adjustment

Order of Testing	Endpoint	TAVR (N=496)	Surgery (N=454)	Treatment Effect [95% CI]	P-value
1	New onset atrial fibrillation at 30 days	5.0%	39.5%	0.10 [0.06, 0.16]	
2	Length of index hospitalization (days)	3.0 (2.0, 3.0)	7.0 (6.0, 8.0)	-4.0 [-4.0, -3.0]	
3	All-cause death, all stroke, or rehospitalizations at 1 year	8.5%	15.1%	0.54 [0.37, 0.79]	
4	Death, KCCQ < 45 or KCCQ decrease from baseline ≥ 10 points at 30 days	3.9%	30.6%	-26.7% [-31.4%, -22.1%]	
5	Death or all stroke at 30 days	1.0%	3.3%	0.30 [0.11, 0.83]	
6	All stroke at 30 days	0.6%	2.4%	0.25 [0.07, 0.88]	

* P-value is Log-Rank test for items 1, 3, 5 and 6; P-value is Wilcoxon Rank-Sum Test for item 2; P-value is Fisher's Exact test for item 4

THE PARTNER 3 TRIAL

Pre-specified Secondary Endpoints

Subject to Multiplicity Adjustment

Order of Testing	Endpoint	TAVR (N=496)	Surgery (N=454)	Treatment Effect [95% CI]	P-value
1	New onset atrial fibrillation at 30 days	5.0%	39.5%	0.10 [0.06, 0.16]	<0.001
2	Length of index hospitalization (days)	3.0 (2.0, 3.0)	7.0 (6.0, 8.0)	-4.0 [-4.0, -3.0]	<0.001
3	All-cause death, all stroke, or rehospitalizations at 1 year	8.5%	15.1%	0.54 [0.37, 0.79]	0.001
4	Death, KCCQ < 45 or KCCQ decrease from baseline ≥ 10 points at 30 days	3.9%	30.6%	-26.7% [-31.4%, -22.1%]	<0.001
5	Death or all stroke at 30 days	1.0%	3.3%	0.30 [0.11, 0.83]	0.01
6	All stroke at 30 days	0.6%	2.4%	0.25 [0.07, 0.88]	0.02

* P-value is Log-Rank test for items 1, 3, 5 and 6; P-value is Wilcoxon Rank-Sum Test for item 2; P-value is Fisher's Exact test for item 4

THE PARTNER 3 TRIAL

Other Secondary Endpoints

Outcomes	30 Days			1 Year		
	TAVR (N=496)	Surgery (N=454)	P-value	TAVR (N=496)	Surgery (N=454)	P-value
Bleeding - Life-threat/Major	3.6% (18)	24.5% (111)	<0.001	7.7% (38)	25.9% (117)	<0.001
Major Vascular Complics	2.2% (11)	1.5% (7)	0.45	2.8% (14)	1.5% (7)	0.19
AKI - stage 2 or 3*	0.4% (2)	1.8% (8)	0.05	0.4% (2)	1.8% (8)	0.05
New PPM (incl baseline)	6.5% (32)	4.0% (18)	0.09	7.3% (36)	5.4% (24)	0.21
New LBBB	22.0% (106)	8.0% (35)	<0.001	23.7% (114)	8.0% (35)	<0.001
Coronary Obstruction	0.2% (1)	0.7% (3)	0.28	0.2% (1)	0.7% (3)	0.28
AV Re-intervention	0% (0)	0% (0)	NA	0.6% (3)	0.5% (2)	0.76
Endocarditis	0% (0)	0.2% (1)	0.29	0.2% (1)	0.5% (2)	0.49
Asymp Valve Thrombosis	0.2% (1)	0% (0)	0.34	1.0% (5)	0.2% (1)	0.13

Event rates are KM estimates (%) and p-values are based on Log-Rank test

* Event rates are incidence rates and p-value is Fisher's Exact test

THE PARTNER 3 TRIAL

Echocardiography Findings

Mean Gradient



No. of Echos			
Surgery	441	426	390
TAVR	483	490	469

P-values are based on the ANCOVA for TAVR vs Surgery adjusted by baseline.

THE PARTNER 3 TRIAL

Echocardiography Findings

Aortic Valve Area



No. of Echos			
Surgery	423	395	371
TAVR	458	470	446

P-values are based on the ANCOVA for TAVR vs Surgery adjusted by baseline.

The PARTNER Trials

Valve Size Distribution





THE PARTNER 3 TRIAL

Paravalvular Regurgitation



P-values are based on the Wilcoxon rank-sum test.

THE PARTNER 3 TRIAL

Paravalvular Regurgitation



P-values are based on the Wilcoxon rank-sum test.

THE PARTNER 3 TRIAL

Functional Assessments



P-values are based on Fisher's Exact test.

P-values are based on the ANCOVA for TAVR vs Surgery adjusted by baseline.

The PARTNER 3 Trial

Study Limitations

- Results only reflect 1-year outcomes; long-term assessment of structural valve deterioration is required
  - 10-year clinical and echocardiographic FU planned in all patients
- Results only apply to the enrolled AS population (e.g. bicuspid aortic valves, non-suitable for TF, and complex CAD excluded)

The PARTNER 3 Trial

Conclusions (1)

In a population of severe symptomatic aortic stenosis patients who were at low surgical risk, TAVR (using the SAPIEN 3 valve) compared to surgery:

- Significantly reduced the primary endpoint of death, stroke, or rehospitalization by 46% at 1-year.
  - Components of the primary endpoint favored TAVR, both at 30 days and 1 year
  - Multiple sensitivity analyses confirmed robustness of the primary endpoint findings

The PARTNER 3 Trial

Conclusions (2)

- Secondary endpoints adjusted for multiple comparisons indicated that TAVR reduced new-onset AF, index hospitalization days, and a measure of poor treatment outcome (death or low KCCQ score at 30 days).
- Other secondary endpoint analyses also showed reduced bleeding after TAVR and no differences in the need for new permanent pacemakers, major vascular complications, coronary obstruction, and mod-severe PVR.
- Some secondary endpoints favored surgery, including reduced new LBBB, reduced mild PVR, and lower aortic valve gradients.

The PARTNER 3 Trial

Conclusions (3)

- TAVR had more rapid post-procedure improvement in patient-oriented functional indices, including NYHA class, 6-minute walking distance, and KCCQ scores.

The PARTNER 3 Trial

Clinical Implications

- *Based upon these findings, TAVR, through 1-year, should be considered the preferred therapy in low surgical risk aortic stenosis patients!*
- *PARTNER randomized trials over the past 12 years, clearly indicate that the relative value of TAVR compared with surgery is independent of surgical risk profiles.*
- *The choice of TAVR vs. surgery in aortic stenosis patients should be a shared-decision making process, respecting patient preferences, understanding knowledge gaps (esp. in younger patients), and considering clinical and anatomic factors.*

The PARTNER 3 Trial

PARTNER 3

- RCT 1:1
- vs. Surgery
- N = 1000 pts

Low Risk



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 OCTOBER 21, 2010 VOL. 363 NO. 17

Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery

Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D., Raj R. Makkar, M.D., David L. Brown, M.D., Peter C. Block, M.D., Robert A. Guyton, M.D., Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D., Howard C. Herrmann, M.D., Pamela S. Douglas, M.D., John L. Petersen, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D., and Stuart Pocock, Ph.D., for the PARTNER Trial Investigators*



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 APRIL 28, 2016 VOL. 374 NO. 17

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients

Martin B. Leon, M.D., Craig R. Smith, M.D., Michael J. Mack, M.D., Raj R. Makkar, M.D., Lars G. Svensson, M.D., Ph.D., Susheel K. Kodali, M.D., Vinod H. Thourani, M.D., E. Murat Tuzcu, M.D., D. Craig Miller, M.D., Howard C. Herrmann, M.D., Darshan Doshi, M.D., David J. Cohen, M.D., Augusto D. Pichard, M.D., Samir Kapadia, M.D., Todd Dewey, M.D., Vasilis Babaliaros, M.D., Wilson Y. Szeto, M.D., Mathew R. Williams, M.D., Dean Kereiakes, M.D., Alan Zajarias, M.D., Kevin L. Greason, M.D., Brian K. Whisenant, M.D., Robert W. Hodson, M.D., Jeffrey W. Moses, M.D., Alfredo Trento, M.D., David L. Brown, M.D., William F. Fearon, M.D., Philippe Pibarot, D.V.M., Ph.D., Rebecca T. Hahn, M.D., Wael A. Jaber, M.D., William N. Anderson, Ph.D., Maria C. Alu, M.M., and John G. Webb, M.D., for the PARTNER 2 Investigators*



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 JUNE 9, 2011 VOL. 364 NO. 23

Transcatheter and Surgical Aortic-Valve Replacement in High-Risk Patients

Craig R. Smith, M.D., Martin B. Leon, M.D., Michael J. Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D., Raj R. Makkar, M.D., Mathew Williams, M.D., Todd Dewey, M.D., Samir Kapadia, M.D., Vasilis Babaliaros, M.D., Vinod H. Thourani, M.D., Paul Corso, M.D., Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D., Howard C. Herrmann, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D., and Stuart J. Pocock, Ph.D., for the PARTNER Trial Investigators*